You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 022450

✉ Email this page to a colleague

NDA 022450 describes OFIRMEV, which is a drug marketed by Mallinckrodt Hosp and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the OFIRMEV profile page.

The generic ingredient in OFIRMEV is acetaminophen. There are sixty-six drug master file entries for this compound. One hundred suppliers are listed for this compound. Additional details are available on the acetaminophen profile page.

Summary for 022450

Tradename:	OFIRMEV
Applicant:	Mallinckrodt Hosp
Ingredient:	acetaminophen
Patents:	4

Medical Subject Heading (MeSH) Categories for 022450

Analgesics, Non-Narcotic
Antipyretics

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS			Strength	1GM/100ML (10MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Nov 2, 2010	TE:		RLD:	Yes
Patent:	10,383,834	Patent Expiration:	Nov 13, 2028	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN
Patent:	10,383,834	Patent Expiration:	Nov 13, 2028	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
Patent:	9,399,012*PED	Patent Expiration:	Mar 11, 2032	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 022450

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mallinckrodt Hosp	OFIRMEV	acetaminophen	SOLUTION;INTRAVENOUS	022450-001	Nov 2, 2010	6,028,222*PED	⤷ Get Started Free
Mallinckrodt Hosp	OFIRMEV	acetaminophen	SOLUTION;INTRAVENOUS	022450-001	Nov 2, 2010	6,992,218*PED	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.